Company Overview - Beijing Baipusi Biotechnology Co., Ltd. is located in Daxing District, Beijing, and was established on July 22, 2010. The company went public on October 18, 2021. Its main business involves providing key biological reagent products and technical services, with revenue composition as follows: 82.27% from recombinant proteins, 12.88% from antibodies and other reagents, 3.04% from technical services, and 1.80% from other sources [1]. Stock Performance - On October 13, Baipusi's stock fell by 5.21%, closing at 58.20 CNY per share, with a trading volume of 138 million CNY and a turnover rate of 1.82%. The total market capitalization is 9.769 billion CNY [1]. Fund Holdings - Silver Hua Fund has a significant position in Baipusi, with its Silver Hua Healthcare Mixed A Fund (018364) holding 40,500 shares, accounting for 5.42% of the fund's net value, making it the third-largest holding. The estimated floating loss today is approximately 129,600 CNY [2]. Fund Manager Performance - The fund manager Zhang Ping has been in position for 6 years and 344 days, managing assets totaling 20.578 billion CNY, with the best fund return during her tenure being 205.15% and the worst being -35.16%. Co-manager Wang Lu has been in position for 2 years and 284 days, managing 2.301 billion CNY, with a best return of 18.53% and a worst return of -2.8% [3].
百普赛斯股价跌5.21%，银华基金旗下1只基金重仓，持有4.05万股浮亏损失12.96万元